leisure time -WSS

leisure time

author：focus 2025-10-02 22:23:47 - browse：242

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

WSS

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Amazon on where the company's health care bets are headed next

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Humana sues Biden admin over Medicare Advantage audit rule

Research misconduct: Proposed new rules face resistance

A rare thyroid diagnosis led to unexpected, all

hotspot

leisure time

knowledge

Guidelines to prevent youth baseball injuries need more muscle

Elizabeth Holmes banned from government health programs

Novavax promises a turnaround & Lilly roils the obesity market

How to protect patients from sexual assault

BioMarin wins approval for gene therapy to treat hemophilia A

A rare thyroid diagnosis led to unexpected, all

Dobbs anniversary: the lost opportunity of abortion as health care

eGenesis tests gene

Hollywood unions extend contract negotiations for actors

Medicaid rebukes states for mistakenly disenrolling children

knowledge

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

NIH director takes cautious approach to Biden drug pricing priority

FDA clears AI tool for detecting skin cancer

'Make People Better': The CRISPR babies story you probably don't know

Listen: Biogen's potential pivot, & Illumina's next chapter

hotspot

hotspot

explore

hotspot